Autolomous

In the most recent instalment of @IBTV’s Movers and Shakers of the week, Autolomous CEO & Co-Founder, Alexander Seyf, shared his experience of Phacilitate’s Advanced Therapies Week whilst highlighting the value of industry collaboration as we head into 2025. Key takeaways include: 👉  Breaking Down Silos, Building Bridges: Historically, the CGT landscape has been fragmented, with researchers, manufacturers, clinicians, and patients operating in relative isolation.  Recently, the need for digitization has been recognized to bridge these gaps and empower stakeholders to collaborate more effectively. 👉 Enhanced Connectivity: Digital platforms foster closer connections between physicians, patients, and the broader industry. Physicians can track patient progress more effectively and industry players can leverage data-driven insights to optimize development strategies whilst simultaneously improving patient access and support. 👉 Ever-increasing Excitement: The overall sentiment surrounding CGT is shifting from cautious optimism to genuine excitement. We're not just seeing progress on the scientific front; we're also witnessing tangible improvements in cost and accessibility. #CellAndGeneTherapy #DigitalTransformation #ATW2025 

🎉 Exciting news for patients with Sickle Cell Disease! CASGEVY® (exagamglogene autotemcel), the first CRISPR/Cas9 #genetherapy for #Sicklecelldisease has been approved for use on the NHS in England, for eligible patients aged 12 and over with severe SCD. SCD is a serious debilitating inherited condition, where misshapen red blood cells block blood flow, leading to intense pain and potentially life threatening complications. This groundbreaking treatment, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, is a huge win for the sickle cell community, marking a leap forward in both patient care and accessibility while providing new hope to individuals and families affected by SCD. Read more here: https://lnkd.in/ehXGQced #Sicklecelldisease #CASGEVY # CRISPR #NHS #Collaboration

💻 It's Monday, and time for our first Movers and Shakers of the week! In this interview, we spoke with Alexander Seyf from Autolomous about all things digital in #CGT! 📈 Alexander goes on to talk about the benefits of collaboration and sharing lessons learned, before going on to talk about his takeaways from Phacilitate's Advanced Therapies Week, as well as what the landscape looks and feels like for 2025. 🎥 For more news and insights from the #ATW25 show floor, you can watch the full series of Movers & Shakers, here: https://lnkd.in/eiViZFv8 #CellTherapy #GeneTherapy #AdvancedTherapies #Digital

Autolomous is thrilled to be featured in Genetic Engineering & Biotechnology News. This article takes a deep dive into Trenchant BioSystems’ innovative new #CGT #manufacturing platform with insights from Jon Ellis of Trenchant BioSystems. 🧬We are excited to integrate autoloMATE with Trenchant’s fully automated CAR-T manufacturing platform, enabling faster manufacturing and lower production costs. 🤝#Collaboration across the industry is crucial for improving patient outcomes and making these life-saving therapies more accessible. 🔗Learn more about how we're working together to drive #scalability in cell and gene therapy: https://lnkd.in/ezpk6icN #Celltherapy #Genetherapy #Partnership #Automation #Innovation

Genetic Engineering & Biotechnology News has just published, through the magic fingers of Gail Dutton, a really interesting deeper dive with Jon Ellis, CEO of Trenchant BioSystems, re their new #CGT #manufacturing systems. These are set to reduce #cellandgenetherapy timeslines from 6 weeks to 2.5 days, and costs by over 80%. Jon also discusses the partnership with Autolomous that will critically #digitalize the manufacturing process. It will be very interesting to see the reaction from this across the industry. https://lnkd.in/dkFATntK

As the cell and gene therapy field continues to innovate and automate itself into more efficient manufacturing processes it is important to remember digitization is equality critical to achieving true scale. For example a typical gene modified autologous therapy might have 50 product traceability events (chain of custody and chain of identity) to track. When that scales to 5,000 patients that is 250,000 events to track (not very efficient using pen and paper)! Autolomous's agnostic digital ecosystem autoloMATE has 25+ integrations (and growing) with tool/equipment providers. https://lnkd.in/dfvA34xs

💡 What’s standing in the way of greater access to cell & gene therapies? Carol Houts, Chief Commercial Officer at Germfree, and Alexander Seyf, CEO of Autolomous unpack this and more in a must-watch fireside chat about ACT of Hope—a new initiative driving collaboration & innovation in advanced therapies. Get the inside scoop on regulatory shifts, manufacturing solutions, and industry impact. Sign up now to receive the full video! 💪➡️ https://hubs.ly/Q0355gjc0 #ATW25 #AdvancedTherapies #PatientAccess #Biopharma

Our team had a fantastic time connecting with industry leaders and experts at Advanced Therapies Week, hosted by Phacilitate in Dallas last week! Our team included CEO and Co-founder Alexander Seyf, COO Walid Fahme, Business Partnership Associates Joanna K., Maxfield Lanzi, Zakiyyah Mangerah and Senior Advisor Luke Thorstenson. We were inspired by the discussions around: 📈 Scaling through technology and automation: Embracing innovation to optimise processes and improve access to life-changing therapies. Early adoption holds immense benefits for long-term development! 🤝 Collaboration is key: By working together, we can tackle the industry’s biggest challenges. We are proud to be at the forefront of Act for Hope, to help drive meaningful change on these pressing issues. 🙍 Prioritising the patient: Developing therapies that truly address patient needs and improve their lives. 💪 Building a strong company culture: Fostering collaboration, purpose and the right leadership is crucial to drive success in the CGT space. We are more committed than ever to our mission of advancing the manufacture and development of CGTs and improving patient lives by enhancing access to these therapies. #ATW25 #Celltherapy #Genetherapy #Innovation #Collaboration

JPM week: A whirlwind of innovation! It seems the entire biotech industry descended on San Francisco earlier in January for the JPM Healthcare Conference. It was an incredible opportunity to connect with current partners and explore exciting collaborations with new ones. From insightful industry briefings to engaging conference sessions and a flurry of networking events, here are some of our key takeaways: ⭐ The FDA is championing the advancement of advanced therapies: We're witnessing a strong push for approvals, reflecting the expanding landscape of these groundbreaking modalities. 🧠 AI is revolutionizing healthcare: From clinical trials to process optimization, the potential applications of AI are vast. However, effective data management and forward-thinking strategies are crucial to unlock its full potential. 💰 Reimbursement remains a critical challenge: Ensuring access to CGTs for patients requires innovative reimbursement models. 🧬 mRNA therapies hold immense promise: These technologies have the potential to revolutionize both cost and access to treatments. 🌎 Global collaboration is essential: The incredible advancements emerging from the global biotech ecosystem highlight the importance of international partnerships. 🙍 Patient, Physician, Payer: This simple yet powerful framework underscores the key stakeholders in bringing life-changing therapies to those who need them most. #JPMorganHealthcare #Biotech #AdvancedTherapies Alexander Seyf Jason Bock Morrie Ruffin

In the latest instalment of Citeline's Scrip Asks, Autolomous CEO & Co-Founder, Alexander Seyf, shared his expertise on the transformative power of AI and data science in the biopharmaceutical industry. In 2025, we'll witness a surge in leveraging AI to tackle complex challenges in producing cutting-edge therapies. Key insights include: 👉 AI will drive advancements in precision medicine, enabling real-time monitoring, predictive maintenance, and process optimization. 👉 This translates to enhanced product consistency, reduced downtime, and accelerated timelines, ultimately benefiting patients. 👉 Growing regulatory support, exemplified by the FDA's accelerated approvals for AI-enabled tools, will further accelerate adoption. At Autolomous, we're at the forefront of this revolution, empowering cell and gene therapy manufacturers to scale their operations through AI-driven solutions. Link in comments ⬇️ #Biopharma #AI #DataScience #CellandGeneTherapy #Innovation #Scrip